Chrysoula Boutari, E. Zarkada, Athanasios Vyzantiadis, E. Vlachaki, Genovefa Mantzou, Cristine Karipidou, S. Theodoridou
{"title":"一名服用文拉法辛的妇女腹前肌出现血肿。类似病例的文献综述。","authors":"Chrysoula Boutari, E. Zarkada, Athanasios Vyzantiadis, E. Vlachaki, Genovefa Mantzou, Cristine Karipidou, S. Theodoridou","doi":"10.1159/000538652","DOIUrl":null,"url":null,"abstract":"INTRODUCTION\nVenlafaxine (VEN) is a selective norepinephrine reuptake inhibitor (SNRI) that mainly helps treat major depressive disorder and anxiety and panic disorders. It works by inhibiting the reuptake of serotonin (5-hydroxytryptamine, 5-HT) and noradrenaline (NA) by presynaptic neurons. Additionally, VEN administration has been linked with a bleeding predisposition, that may be due to the inhibition of NA and 5-HT uptake by platelets which have their own receptors on their surface and are implicated in platelet aggregation.\n\n\nCASE PRESENTATION\nHerein, we report a case of a 54-year-old patient treated with VEN, who presented with a hematoma in the anterior abdominal muscle. We also present the observational studies and case reports highlighting the association of SNRIs use with various hemorrhagic complications ranging from gastrointestinal hemorrhage or vaginal bleeding to bleeding during or after surgery due to either thrombocytopenia or impaired platelet aggregation.\n\n\nCONCLUSION\nGiven the cases of either reductions in the platelet count or impairment of platelet activity accompanied by bleeding events, every clinician should be aware of these possible adverse effects when prescribing SNRIs.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A hematoma in the anterior abdominal muscle in a woman receiving venlafaxine. A literature review of the reports on similar cases.\",\"authors\":\"Chrysoula Boutari, E. Zarkada, Athanasios Vyzantiadis, E. Vlachaki, Genovefa Mantzou, Cristine Karipidou, S. Theodoridou\",\"doi\":\"10.1159/000538652\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"INTRODUCTION\\nVenlafaxine (VEN) is a selective norepinephrine reuptake inhibitor (SNRI) that mainly helps treat major depressive disorder and anxiety and panic disorders. It works by inhibiting the reuptake of serotonin (5-hydroxytryptamine, 5-HT) and noradrenaline (NA) by presynaptic neurons. Additionally, VEN administration has been linked with a bleeding predisposition, that may be due to the inhibition of NA and 5-HT uptake by platelets which have their own receptors on their surface and are implicated in platelet aggregation.\\n\\n\\nCASE PRESENTATION\\nHerein, we report a case of a 54-year-old patient treated with VEN, who presented with a hematoma in the anterior abdominal muscle. We also present the observational studies and case reports highlighting the association of SNRIs use with various hemorrhagic complications ranging from gastrointestinal hemorrhage or vaginal bleeding to bleeding during or after surgery due to either thrombocytopenia or impaired platelet aggregation.\\n\\n\\nCONCLUSION\\nGiven the cases of either reductions in the platelet count or impairment of platelet activity accompanied by bleeding events, every clinician should be aware of these possible adverse effects when prescribing SNRIs.\",\"PeriodicalId\":6981,\"journal\":{\"name\":\"Acta Haematologica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-04-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Haematologica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000538652\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538652","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
简介 文拉法辛(VEN)是一种选择性去甲肾上腺素再摄取抑制剂(SNRI),主要用于治疗重度抑郁症、焦虑症和恐慌症。它通过抑制突触前神经元对血清素(5-羟色胺,5-HT)和去甲肾上腺素(NA)的再摄取而发挥作用。此外,服用 VEN 与出血倾向有关,这可能是由于抑制了血小板对 NA 和 5-HT 的摄取,而血小板表面有自己的受体,与血小板聚集有关。我们还介绍了一些观察性研究和病例报告,这些研究和报告强调了 SNRIs 的使用与各种出血并发症的关联,这些并发症包括胃肠道出血或阴道出血,以及由于血小板减少或血小板聚集功能受损导致的术中或术后出血。
A hematoma in the anterior abdominal muscle in a woman receiving venlafaxine. A literature review of the reports on similar cases.
INTRODUCTION
Venlafaxine (VEN) is a selective norepinephrine reuptake inhibitor (SNRI) that mainly helps treat major depressive disorder and anxiety and panic disorders. It works by inhibiting the reuptake of serotonin (5-hydroxytryptamine, 5-HT) and noradrenaline (NA) by presynaptic neurons. Additionally, VEN administration has been linked with a bleeding predisposition, that may be due to the inhibition of NA and 5-HT uptake by platelets which have their own receptors on their surface and are implicated in platelet aggregation.
CASE PRESENTATION
Herein, we report a case of a 54-year-old patient treated with VEN, who presented with a hematoma in the anterior abdominal muscle. We also present the observational studies and case reports highlighting the association of SNRIs use with various hemorrhagic complications ranging from gastrointestinal hemorrhage or vaginal bleeding to bleeding during or after surgery due to either thrombocytopenia or impaired platelet aggregation.
CONCLUSION
Given the cases of either reductions in the platelet count or impairment of platelet activity accompanied by bleeding events, every clinician should be aware of these possible adverse effects when prescribing SNRIs.
期刊介绍:
''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.